A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome
ISRCTN | ISRCTN38366450 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN38366450 |
Secondary identifying numbers | Version 2 |
- Submission date
- 14/04/2006
- Registration date
- 07/07/2006
- Last edited
- 16/09/2013
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Fang Gao
Scientific
Scientific
Adult Intensive Care Unit
Birmingham Heartlands Hospital
Bordesley Green East
Birmingham
B9 5SS
United Kingdom
Study information
Study design | Randomised, double-blind, placebo-controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Not specified |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | |
Study acronym | BALTI-2 |
Study objectives | In patients with acute respiratory distress syndrome (ARDS), treatment with intravenous salbutamol will reduce 28-day mortality |
Ethics approval(s) | West Midlands Multicentre Research Ethics Committee, approval pending as of 01/05/2006 |
Health condition(s) or problem(s) studied | Acute respiratory distress syndrome |
Intervention | Salbutamol or placebo will be administered through a dedicated intravenous line for seven days |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Salbutamol |
Primary outcome measure | Mortality 28 days after randomisation |
Secondary outcome measures | 1. Number of ventilator-free days 2. Mortality at (first) discharge from ICU 3. Mortality at discharge from hospital 4. Mortality at 12 months post randomisation 5. ICU length of stay 6. Hospital length of stay 7. Disability and quality of life at 12 months after randomisation |
Overall study start date | 01/08/2006 |
Completion date | 01/09/2007 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Lower age limit | 18 Years |
Sex | Both |
Target number of participants | 100 |
Key inclusion criteria | On day 1 following intensive care unit (ICU) admission, the primary caring ICU clinician should consider all adult patients (age ≥18 years) with severe hypoxaemic respiratory failure (PaO2/FiO2) ≤26.7 kPa to be eligible for inclusion in the trial |
Key exclusion criteria | 1. Pregnancy 2. Cardiogenic pulmonary oedema (confirmed by medical history and chest x-ray) 3. Severe obstructive airway disease requiring nebulised or intravenous (IV) beta 2-agonists 4. Treatment with beta 2-blockers ≤48 hours 5. Brain stem death 6. Treatment withdrawal ≤24 hours, which indicates any interventions (including a trial) would be considered inappropriate 7. Refusing consent or patients in whom relatives refuse assent 8. Enrolled in another interventional clinical trial in the last 28 days |
Date of first enrolment | 01/08/2006 |
Date of final enrolment | 01/09/2007 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centre
Adult Intensive Care Unit
Birmingham
B9 5SS
United Kingdom
B9 5SS
United Kingdom
Sponsor information
Heart of England NHS Foundation Trust (UK)
Hospital/treatment centre
Hospital/treatment centre
Birmingham Heartlands Hospital
Bordesley Green East
Birmingham
B9 5SS
England
United Kingdom
Funders
Funder type
Research organisation
Intensive Care Society
Private sector organisation / Associations and societies (private and public)
Private sector organisation / Associations and societies (private and public)
- Alternative name(s)
- ICS
- Location
- United Kingdom
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 09/05/2011 | Yes | No | |
Results article | results | 21/01/2012 | Yes | No | |
Results article | results | 01/09/2013 | Yes | No |